Log in to search using one of your social media accounts:

 

Hancock Jaffe re-sets the range for $8m IPO
Medical device developer Hancock Jaffe Laboratories yesterday re-set the range on a pending initial public offering, which would fetch roughly $8 million at the midpoint. Irvine, Calif.-based Hancock Jaffe makes bioprosthetic implants designed to treat chronic deep vein insufficiency, heart valve conditions and coronary artery bypass graft. Last December the company said it planned to float nearly 1.9 million shares at $6 to $8 apiece, for gross proceeds of $11.3 million to $15.0 million, or $13.1 million at the midpoint. In a new filing yesterday, Hancock Jaffe cut the amount of shares to roughly 1.1 m...
Source: Mass Device - May 23, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Initial Public Offering (IPO) Vascular Wall Street Beat hancockjaffelabs Source Type: news

Extended INR Test Intervals Safe for Warfarin-Treated Patients
WEDNESDAY, May 23, 2018 -- For stable warfarin-treated patients, extended international normalized ratio (INR) testing can be successfully and safely implemented, according to a study published online May 15 in the Journal of Thrombosis and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 23, 2018 Category: Pharmaceuticals Source Type: news

Inari Medical wins FDA 510(k) for FlowTriever
Inari Medical said today it won FDA 510(k) clearance for its FlowTriever stent retriever designed to treat pulmonary embolisms. The clearance came based upon results from the company’s Flare clinical study of the device, which examined data from 106 patients with acute pulmonary embolisms treated with the FlowTriever at 18 US sites, the Irvine, Calif.-based company said. Results from the study indicated a decrease in mean RV/LV ratio from baseline of 1.53 to 1.15 at 48 hours post-procedure. Data also indicated excellent safety at 30 days with a 3.8% rate of major adverse events and no device related complication...
Source: Mass Device - May 22, 2018 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Regulatory/Compliance Vascular Inari Medical Source Type: news

Rivaroxaban Linked to Low VTE Recurrence in Active Cancer
MONDAY, May 21, 2018 -- For patients with active cancer and venous thromboembolism (VTE), rivaroxaban is associated with lower VTE recurrence compared with dalteparin, but with elevated clinically relevant non-major bleeding (CRNMB), according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 21, 2018 Category: Pharmaceuticals Source Type: news

What is BACM?
Discussion Leg pain in children has a broad differential diagnosis and includes more innocuous problems such as growing pains and transient synovitis but also more serious problems including neurological diseases or malignancy. Occult or self-limited trauma are also common causes. A review can be found here. Limping can be painful or painless and has its own differential diagnosis which can overlap with leg pain. A differential diagnosis for limping can be found here. Muscle weakness also has its’ own differential diagnosis which can be found here. Learning Point Benign acute childhood myositis (BACM) has other names...
Source: PediatricEducation.org - May 21, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

May 18, 2018 This Week in Cardiology May 18, 2018 This Week in Cardiology
Device-related thrombosis with Watchman left atrial appendage closure, debulking atrial fibrillation after ablation, rivaroxaban for stroke prevention, alteplase, and Lp(a) are discussed this week.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 18, 2018 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

SurModics acquires Embolitech thrombectomy tech for $5m
SurModics (NSDQ:SRDX) said today it inked a deal with Embolitech to acquire its thrombectomy platform the and associated intellectual property in a deal worth $5 million up front, with additional payments based on regulatory milestones. The newly acquired tech platform is designed for use in the peripheral vasculature to remove hard blood clots, Eden Prairie, Minn.-based SurModics said. SurModics added that it plans to leverage its design, development and manufacturing capabilities to advance the platform into different peripheral and vascular applications. “We are pleased to sign an agreement with Surmodic...
Source: Mass Device - May 14, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Catheters Mergers & Acquisitions Vascular SurModics Inc. Source Type: news

Strokes From Clot on Watchman LAA Closure Device: OAC Insights Strokes From Clot on Watchman LAA Closure Device: OAC Insights
The risks for ischemic and hemorrhagic stroke climbed whenever thrombus was seen on the implanted left atrial appendage occluder, often after oral anticoagulants were halted, in a pooled analysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 14, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

HRS 2018: Device-related blood clots with Boston Scientific ’ s Watchman implant
Data from a study of device-related blood clots and the Watchman cardiac implant made by Boston Scientific (NYSE:BSX), presented today at the annual meeting of the Heart Rhythm Society in Boston, indicate the need for aggressive management of patients at risk for device-related thrombosis. There were 74 incidences of DRT in 65 of the 1,739 Watchman patients examined in the study, or 3.7%; eight of those patients had multiple DRTs and two experienced embolic events (0.45%). There was no significant difference in mortality between patients with DRT and those without, according to the study. Lead author Dr. Vivek Reddy, ...
Source: Mass Device - May 11, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Boston Scientific HRS 2018 Source Type: news

HRS 2018 Roundup: Device-related blood clots with Boston Scientific ’ s Watchman implant
Data from a study of device-related blood clots and the Watchman cardiac implant made by Boston Scientific (NYSE:BSX), presented today at the annual meeting of the Heart Rhythm Society in Boston, indicate the need for aggressive management of patients at risk for device-related thrombosis. There were 74 incidences of DRT in 65 of the 1,739 Watchman patients examined in the study, or 3.7%; eight of those patients had multiple DRTs and two experienced embolic events (0.45%). There was no significant difference in mortality between patients with DRT and those without, according to the study. Lead author Dr. Vivek Reddy, ...
Source: Mass Device - May 11, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Apple Bardy Diagnostics Boston Scientific Fitbit HRS 2018 Impulse Dynamics Imricor Medical Systems Inc. medicalgorithmics Medtronic Preventice samsung Source Type: news

Investors win class certification in lawsuit against Abbott ’ s Thoratec
A group of Thoratec shareholders this week won a class certification in a revived suit claiming that Thoratec, now owned by Abbott (NYSE:ABT), and some of its officers hid facts about its HeartMate II heart pump’s rate of thrombosis that would have negatively affected share prices, thereby misleading investors. Investor Bradley Cooper originally brought the suit against the company in January 2014, on behalf of anyone who bought stock between April 29, 2010, and Nov. 27, 2013. Plaintiffs in the case argued that the company failed to warn investors about a blood clot problem with its HeartMate II i...
Source: Mass Device - May 10, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Legal News Abbott Thoratec Corp. Source Type: news

Perioperative VTE in Urologic Oncology Procedures Perioperative VTE in Urologic Oncology Procedures
Learn more about the risk for venous thromboembolism among patients undergoing major urologic oncology operations, and find out how best to prevent this complication.Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 10, 2018 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

Doctors Beware: Abbott & #039;s HeartMate 3 Has a Safety Problem
Just when it seemed the HeartMate 3 was gaining momentum, Abbott warned physicians that outflow graft twisting may occur after the left ventricular assist device (LVAD) is implanted. The problem can trigger a persistent low-flow alarm that may signal a potential safety risk to patients, such as blood flow or clotting. The Abbott Park, IL-based company has not recalled any of the devices from patients or hospitals, but there have been 32 reports of outflow graft twisting (an incidence rate of 0.72%), including reports of low blood flow, clotting, and three patient deaths. No devices are being recalled from patients or ...
Source: MDDI - May 7, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Implants Source Type: news

Inari Medical touts FlowTriever pulmonary embolism study data
Inari Medical today presented results from a study of its FlowTriever retrieval and aspiration system designed to treat pulmonary embolism, touting the safety and efficacy of the system. Results were presented by Dr. Thomas Tu of Louisville, Ky.’s Baptist Health at the Scientific Sessions of the Society for Cardiovascular Angiography and Interventions in San Diego, Irvine, Calif.-based Inari Medical said. “The significant improvement in right heart function shown with the FlowTriever system compares very favorably with outcomes of other techniques used to treat PE. At the same time, the impressive safety profil...
Source: Mass Device - April 30, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Vascular Inari Medical Source Type: news

Tenecteplase: Thrombolytic of Choice in Stroke? Tenecteplase: Thrombolytic of Choice in Stroke?
The EXTEND-IA TNK trial suggesting better outcomes with tenecteplase than alteplase in the treatment of acute ischemic stroke has now been published in the New England Journal of Medicine.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - April 26, 2018 Category: Intensive Care Tags: Neurology & Neurosurgery News Source Type: news

Health Tip: Factors That Raise Risk of Blood Clot
-- Blood clots can dissolve on their own, but don't always. Deep vein thrombosis (DVT)is a type of clot that tends to form in a major vein of the leg, although it can form in other parts of the body, too. The clot ultimately can travel through the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 26, 2018 Category: General Medicine Source Type: news

tPA in Stroke:'The Facts Are Clear'tPA in Stroke:'The Facts Are Clear '
Thrombolytic treatment for stroke remains controversial among specialties. Here, a neurologist argues for its use.Medscape Neurology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 20, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery Expert Column Source Type: news

Tetherex Pharmaceuticals, Inc. Completes $50M Series B Financing
Funding to support Phase 2 clinical trials of the company's PSGL-1 inhibitor, SelK2, in multiple indications OKLAHOMA CITY, April 18, 2018 -- (Healthcare Sales & Marketing Network) -- Tetherex Pharmaceuticals, Inc., a privately held biopharmaceutical c... Biopharmaceuticals, Venture Capital Tetherex Pharmaceuticals, venous thromboembolism, PSGL-1, SelK2 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 18, 2018 Category: Pharmaceuticals Source Type: news

Three-fold higher risk of cancer after acute thrombosis in the leg
(Aarhus University) The risk of developing cancer is more than three times higher during the first six months following blood clot in the leg, compared with the background population. This is shown by a register-based study that medical doctor and Ph.D. Jens Sundb ø ll has recently published in the journal Circulation. Jens Sundb ø ll is employed at the Department of Clinical Epidemiology, which is part of the Department of Clinical Medicine at Aarhus University and Aarhus University Hospital. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 16, 2018 Category: International Medicine & Public Health Source Type: news

What Are Complications of Oropharyngeal Trauma?
Discussion Oropharyngeal trauma is common and ranges from minor contusions to severe trauma of the head and neck. Sudden movement while having a foreign object in the mouth is a very common scenario with falls or collisions being common mechanisms. Common objects include toys, sticks, pens/pencils, chopsticks, toothbrushes, and popsicle sticks. Many of these injuries cause minimal problems such as a contusion to lips (i.e. “fat lip”). In general, the more anterior the location the more common the injury and the less likely to have a severe injury (i.e. lips). Whereas posterior structures are more protected, bu...
Source: PediatricEducation.org - April 16, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

The Case Against Thrombolytic Therapy in Stroke The Case Against Thrombolytic Therapy in Stroke
A New York Times article siding with neurologists in their debate with emergency medicine over the benefits of tPA in ischemic stroke prompted Dr Mandrola to take a closer look at the data.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 13, 2018 Category: Consumer Health News Tags: Cardiology Expert Column Source Type: news

Medical News Today: What causes calf muscle pain?
Calf muscle pain is often caused by overuse or a sports injury. However, it can also indicate an underlying medical issue, including deep vein thrombosis or diabetic neuropathy. Learn more about the causes of calf muscle pain, as well as what stretches can provide relief and when you should see a doctor. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 10, 2018 Category: Consumer Health News Tags: Pain / Anesthetics Source Type: news

An Alternative to Dalteparin for Cancer-Related VTE An Alternative to Dalteparin for Cancer-Related VTE
Dr David Kerr discusses a promising new study suggesting that oral edoxaban may be substituted for daily subcutaneous dalteparin in cancer patients who have had a venous thromboembolism.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Inari Medical Announces Completion of $27 Million Series C Financing
IRVINE, Calif., March 29, 2018 -- (Healthcare Sales & Marketing Network) -- Inari Medical, Inc., announced today the close of a Series C financing totaling $27.0 million. The financing was led by new investor Gilde Healthcare and was joined by all of Ina... Devices, Interventional, Venture Capital Inari Medical, FlowTriever, ClotTriever, venous thromboembolism, thrombectomy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 29, 2018 Category: Pharmaceuticals Source Type: news

Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union
SOUTH SAN FRANCISCO, Calif., March 23, 2018 -- (Healthcare Sales & Marketing Network) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ... Biopharmaceuticals, Regulatory Portola Pharmaceuticals, Bevyxxa, betrixaban, venous thromboembolism (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 23, 2018 Category: Pharmaceuticals Source Type: news

ask Warning Signs of Deep Vein Thrombosis dvt
What Are the Warning Signs of Deep Vein Thrombosis (DVT)? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 20, 2018 Category: General Medicine Source Type: news

MIT study reveals the problem with bioresorbable stents
Image courtesy of Pei-Jiang Wang Bioresorbable coronary scaffolds, designed to avoid the risks associated with the long-term implantation of metal stents, once captured the attention of medtech giants like Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX). But companies have since linked the use of these biodegradable polymer-based devices to a heightened risk of myocardial infarction and thrombosis, prompting Abbott to pull its Absorb product from the market and Boston Scientific to terminate its Renuvia scaffold development program last year. Get the full story at our sister site,...
Source: Mass Device - March 15, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Blog Abbott Boston Scientific Massachusetts Institute of Technology Source Type: news

Structure of blood-clotting receptor identified
P2Y12 receptor plays a key role in blood clotting by communicating with molecules to induce platelet clustering and subsequent thrombus (blood clot) formation. (Source: NIDDK News)
Source: NIDDK News - March 15, 2018 Category: Endocrinology Source Type: news

MOMENTUM 3: HeartMate 3 Improves Stroke-Free Survival at 2 Years MOMENTUM 3: HeartMate 3 Improves Stroke-Free Survival at 2 Years
The result in patients with advanced heart failure, showing a'dramatic reduction in pump thrombosis requiring reoperation -- essentially 0% -- really is a game changer,'says one expert.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 13, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Abbott Gains on Medtronic in LVAD Market
Abbott Laboratories said late-breaking clinical trial data from its MOMENTUM 3 clinical study shows its HeartMate 3 Left Ventricular Assist Device (LVAD) has improved survival and lowered rates of stroke and pump thrombosis. The Abbott Park, IL-based company released the data during the American College of Cardiology’s 67th Annual Scientific Sessions this past weekend. Data from MOMENTUM 3 was also published in the New England Journal of Medicine and showed patients with the HeartMate 3 LVAD had a survival rate of 82.8% at two years compared with 76.2% for those with the HeartMate II LVAD. Pump thrombosis rates remai...
Source: MDDI - March 12, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news

ACC ’ 18 Roundup: Abbott releases long-term HeartMate 3 data
Abbott (NYSE:ABT) touted two-year data yesterday from its trial designed to compare the company’s HeartMate 3 left ventricular assist device to its HeartMate 2 device in patients with advanced heart failure. Data from the study were published in The New England Journal of Medicine and presented at the American College of Cardiology’s 67th Annual Scientific Session. More than 1,000 patients participated in the study. Researchers assessed the trial’s participants for a short-term endpoint of six months and long-term endpoint of two years. The two-year cohort met its primary endpoint, achieving 77....
Source: Mass Device - March 12, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiac Assist Devices Cardiac Implants Cardiovascular Clinical Trials Diagnostics Food & Drug Administration (FDA) Regulatory/Compliance Research & Development Wall Street Beat Abbott Aetna AliveCor iRhythm Technologies Inc. Jan Source Type: news

COMBO Stent Impresses at 1 Year in'All-Comers' Registry COMBO Stent Impresses at 1 Year in'All-Comers' Registry
Although randomized results are still awaited, real-world registry results with the COMBO stent, designed to regenerate endothelium and reduce in-stent thrombosis, are'exciting,'researchers say.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 12, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

ACC: HeartMate 3 LVAD Still Free from Significant Pump Thrombosis at 2 Years (CME/CE)
(MedPage Today) -- Follow-up of MOMENTUM 3 confirms 6-month data for newer device (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 11, 2018 Category: Cardiology Source Type: news

New Long-Term Data Show Improved Survival and Lower Rates of Stroke and Pump Thrombosis for Abbott's HeartMate 3 Heart Pump
-- HEARTMATE 3 ™ LVAD DEMONSTRATED IMPROVED CLINICAL OUTCOMES OVER THE MOST WIDELY USED LVAD IN THE WORLD (Source: Abbott.com)
Source: Abbott.com - March 11, 2018 Category: Pharmaceuticals Source Type: news

Survivors of childhood cancer are at great risk of heart problems in adulthood
(European Society of Cardiology) A study of nearly 1,000 survivors of childhood cancer has found that they are at increased risk of suffering prematurely from cardiovascular disease in adulthood. Childhood cancer survivors had a nearly two-fold increased risk of cardiovascular diseases such as congestive heart failure and venous thromboembolism, and were at increased risk of having high blood pressure and dyslipidaemia. The study is published in the European Heart Journal. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 8, 2018 Category: Cancer & Oncology Source Type: news

After Many Missteps, Endologix Makes Progress on Nellix
Endologix just took a big step forward on what has been a long and winding road to FDA approval of its Nellix endovascular aneurysm sealing (EVAS) system. The Irvine, CA-based company said the first patient was treated in its EVAS2 confirmatory clinical study of the device. The Nellix System was developed as an alternative treatment to traditional endovascular aneurysm repair (EVAR) for an abdominal aortic aneurysm (AAA). The system is designed to seal an entire aneurysm. Endologix originally planned to have FDA approval of the Nellix system by the end of 2016, but the company hit a speed bump about midway through that yea...
Source: MDDI - March 5, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Medical Device Business Regulatory and Compliance Source Type: news

Varicose Veins Tied to Higher Risk for Deep Venous Thrombosis Varicose Veins Tied to Higher Risk for Deep Venous Thrombosis
Adults with varicose veins are at significantly increased risk for incident deep venous thrombosis, a large retrospective cohort study has found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 28, 2018 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Varicose Veins Tied to Higher Odds for Blood Clots
TUESDAY, Feb. 27, 2018 -- Those tangled blue varicose veins that can pop up on your legs as you age may be more than unsightly: New research suggests they might quintuple your risk of dangerous blood clots. Known as deep venous thrombosis (DVT),... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 27, 2018 Category: General Medicine Source Type: news

How Do Deep Neck Infections Present?
Discussion Deep neck space infections (DNSI) are not very common (estimated to be 4.6/100,000) but extremely important to have a high index of suspicion for. The anatomy of DNSs is complex and covered by substantial amounts of superficial soft tissue making diagnosis difficult. Additionally, children often cannot give more precise or accurate histories and can be difficult to examine> Most infections in children are in those
Source: PediatricEducation.org - February 26, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Second Opinion | Long flight? Staying home and binge watching TV? Risk of deep vein thrombosis either way
That deep vein thrombosis risk you've heard about on long flights? It can also happen after binge watching TV, researchers say. (Source: CBC | Health)
Source: CBC | Health - February 24, 2018 Category: Consumer Health News Tags: News/Health Source Type: news

Ask Feel Like Have Deep Vein Thrombosis symptoms
What Does It Feel Like When You Have a Blood Clot in Your Leg (DVT)? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - February 23, 2018 Category: General Medicine Source Type: news

Too Much TV Could Boost Your Odds for a Blood Clot
The study found that people who spend too much time in front of the TV are at increased risk for blood clots in their veins -- a condition called venous thromboembolism (VTE). (Source: WebMD Health)
Source: WebMD Health - February 22, 2018 Category: Consumer Health News Source Type: news

Medical News Today: How too much TV could kill you
You might think binge-watching your favorite show is harmless, but a new study finds that too much TV could raise the risk of potentially fatal blood clots. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 22, 2018 Category: Consumer Health News Tags: Venous Thromboembolism (VTE) Source Type: news

FDA clears Access Vascular ’ s HydroPICC catheter
Access Vascular said today that its HydroPICC catheter has won 510(k) clearance from the FDA. The peripherally-inserted central catheter is designed with Access Vascular’s proprietary bulk-hydrophilic material, which the company touted as “the ideal material for long-term implantable vascular access devices.” “The FDA clearance of the HydroPICC catheter is an important milestone for Access Vascular and a critical step forward on our pathway to commercialization,” founder, president & CEO, James Biggins, said in prepared remarks. “Today’s news is a validation of our team&rs...
Source: Mass Device - February 22, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: 510(k) Catheters Food & Drug Administration (FDA) Regulatory/Compliance Vascular accessvascular Source Type: news

Access Vascular Receives FDA Clearance For Its HydroPICC Catheter
The HydroPICC Uses Proprietary Technology Designed to Reduce Thrombosis BEDFORD, Mass., Feb. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Access Vascular, a medical device company reinventing venous access using proprietary material technology... Devices, FDA Access Vascular, HydroPICC, peripherally inserted central catheter (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 22, 2018 Category: Pharmaceuticals Source Type: news

Watching too much television could cause fatal blood clots
University of Minnesota scientists found the risk of venous thromboembolism remained high, even when weight and exercise levels were taken into account after analysing data from 15,000 adults. (Source: the Mail online | Health)
Source: the Mail online | Health - February 21, 2018 Category: Consumer Health News Source Type: news

Turn off the telly and get moving
(Springer) Spending too much time in front of the television could increase your chance of developing potentially fatal blood clots known as venous thrombosis. Even trying to counterbalance hours of TV watching through adequate exercise is not effective warns Yasuhiko Kubota of the University of Minnesota in the US. Kubota is the lead author of a study in Springer's Journal of Thrombosis and Thrombolysis. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 21, 2018 Category: International Medicine & Public Health Source Type: news

More Evidence Migraine Ups Cardiovascular Disease Risk More Evidence Migraine Ups Cardiovascular Disease Risk
This study expands the findings to include venous thromboembolism, atrial fibrillation, and other cardiovascular diseases.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 13, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

BTG touts one-year follow-up data for Ekos pulmonary embolism therapy
BTG (LON:BTG) touted results today from a one-year follow-up of pulmonary embolism patients who received the company’s Ekos therapy in its Optalyse PE trial. Researchers studied the 12-month outcomes of 101 patients who were treated over a shorter period and with smaller doses of thrombolytic drugs compared to the current standard. Pulmonary embolism patients treated with BTG’s Ekos device and anti-coagulation drugs received therapy in as little as two hours with a tissue plasminogen activator dose as low as 8 mg, the company reported. Get the full story at our sister site, Drug Delivery Business...
Source: Mass Device - February 6, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Drug-Device Combinations Pharmaceuticals Wall Street Beat BTG Source Type: news

Thromboembolism Less Likely With LAA Closure Added to Cardiac Surgery
(MedPage Today) -- Concomitant procedure tied to fewer events, registry data shows (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 23, 2018 Category: Cardiology Source Type: news